CASE CCC IN THE NEWS
Making the Most of Media Coverage: The Case Comprehensive Cancer Center Experience
AACI Commentary - Fall 2013
Stanton L. Gerson, MD, Director of the Case Comprehensive Cancer Center in Cleveland, discusses thePlain Dealer "Clues to Cancer" series and offers insight on how cancer centers can actively engage the media and encourage their continued interest in our work.
Functional Disability High Among Newly Diagnosed Older Breast Cancer Patients
Science Daily - Sept 23, 2013
Many older women with newly diagnosed breast cancer have difficulty accomplishing daily tasks, and African-Americans seem to be disproportionately affected. Those are the findings of a new study published early online in Cancer, a peer-reviewed journal of the American Cancer Society...Case Comprehensive Cancer Center member Cynthia Owusu, MD, MS, of the Case Western Reserve University School of Medicine and University Hospitals Case Medical Center in Cleveland, and her colleagues looked to see if there are racial differences in functional disability among older women with newly diagnosed breast cancer.
UH Seidman Cancer Center Breaks Ground on $30 Million Proton Therapy Center
The Herald - Sept 20, 2013
University Hospitals Seidman Cancer Center is breaking ground today on a $30 million proton therapy center, becoming one of an elite group of cancer centers in the country to offer this revolutionary technology..."There are several benefits to the delivery of radiation treatment with protons rather than photons for certain types of cancer, and we believe that this represents the next important advancement in radiation therapy. We are very excited to bring this leading-edge technology to Ohio," says Nathan Levitan, MD, President, UH Seidman Cancer Center..."Proton beams have unique physical properties that allow reduced doses of radiation to uninvolved normal tissue," says David Mansur, MD, Director of the Proton Therapy Center..."With the addition of a proton beam facility, we will be able to offer a full array of the latest in cutting edge radiotherapy," says Mitch Machtay, MD, Chairman of Radiation Oncology at UH Case Medical Center and Case Western Reserve University School of Medicine..."Building a proton therapy center is a huge boon for our patients as well as this entire region," says Stan Gerson, MD, Director of the UH Seidman Cancer Center and the Case Comprehensive Cancer Center.
Internationally Recognized Gene Therapy Investigators Release Book Chronicling Latest Advances in Cancer Treatment
Newswise - Sept 19, 2013
The field of gene therapy promises to dramatically transform the treatment of disease, as well as fundamentally change the delivery of healthcare in the twenty-first century. With an acceleration of advances taking place in the field, a new book provides a comprehensive review of the field of gene-based therapeutics in an expanded third edition textbook that concentrates on advances in areas that were in their infancy when the last edition was published in 2002. The new book,Gene Therapy of Cancer Translational Approaches from Preclinical Studies to Clinical Implementation 3 (Elsevier Limited, Oxford, United Kingdom) is co-edited by internationally recognized investigators Stanton L. Gerson, MD, Director of the Case Comprehensive Cancer Center, and Edmund C. Lattime, PhD, Rutgers Cancer Institute of New Jersey.
Cleveland Clinic Forms Spinoff-company to Move its Breast Cancer Vaccine to Clinical Trials
Yahoo Health - Sept 18, 2013
A Cleveland Clinic researcher who has spent the past 11 years working on a breast cancer vaccine that would both prevent the disease and keep it from recurring has secured enough funding to move the drug to clinical trials. Vincent Tuohy, an immunologist at the Clinic's Lerner Research Institute and member of the Case Comprehensive Cancer Center, will head up the company, called Shield Biotech, as its chief science officer. Shield Biotech, so named because the vaccine it is developing will act as a defense against breast cancer, is a spinoff-company created by Cleveland Clinic Innovations, the commercialization arm of the hospital system.
Study Sheds New Light On The Appropriate Role Of Reduced-Intensity Donor Transplantation In Older MDS Patients
MDS Beacon - Sept 18, 2013
A recent international study provides new insights into the appropriate role of reduced-intensity donor stem cell transplantation in the care of older people with myelodysplastic syndromes...In an editorial that accompanied the study, Case Comprehensive Cancer Center member Dr. Mikkael Sekeres from the Cleveland Clinic explained that, with a median age of 64 years, the patients included in Dr. Koreth's study more closely resemble the MDS patients typically seen by physicians, compared to the patients previously included in studies investigating when to use stem cell transplantation for MDS.
Immune Checkpoint Inhibition in Renal Cell Carcinoma
OncLive - Sept 18, 2013
Dr. Brian Rini, professor and staff in the department of Solid Tumor Oncology at the Cleveland Clinic Taussig Cancer Institute and Co-Leader of the GU Malignancies Program at the Case Comprehensive Cancer Center, joins a panel of experts to discuss immune checkpoint inhibition in renal cell carcinoma.
Despite Headlines, Role of Statins in Cancer Prevention Far from Proven
Helio/Cardiology Today - Sept 2013
The potential role of statins in cancer prevention has received tremendous attention from the medical research community and the media..."It shows up on the news that statins are protective of cancer," Dale R. Shepard, MD, PhD, staff physician in the department of solid tumor oncology at Cleveland Clinic's Taussig Cancer Institute and Case Comprehensive Cancer Center, said in an interview..."There is strong experimental evidence that some of the actions of statins may occur independent of their lipid-lowering effects,"Mukesh K. Jain, MD, Case Comprehensive Cancer Center member, professor of medicine, and director of the Case Cardiovascular Research Institute at Case Western Reserve University, Cleveland, told Cardiology Today.
AACR Cancer Cancer Progress Report 2013
The American Association for Cancer Research (AACR) Cancer Progress Report 2013 is now available. As in past years, this year's Cancer Progress Report continues to highlight the many advances and breakthroughs in cancer treatment and emphasizes the need for continued investment in cancer research.
|Dr. Nathan Berger served on the report's writing committee, and wrote the section on Energy Balance and Cancer, including the sections on Sleep, Obesity, Diabetes and Physical Activity.|
MARK YOUR CALENDARS
Breast Cancer Program Meeting
The Breast Cancer Program will hold its first monthly working group meeting today, September 23 from 4-5 pm in Wolstein 3-136. This first meeting will be an introductory/business meeting to present the program structure, its leaders, focus groups, resources, etc, as well as a means to hear membership ideas to improve, strengthen, and build the program. Parking will be validated. Please RSVP to email@example.com.
Basic Sciences Program Mini-Retreat
The Basic Sciences Program, led by Drs. Clark Distelhorst and Alex Almasan, will be hosting a mini-retreat onThursday, September 26 from 1-5 pm in WRB 3-136. The retreat will explain the restructuring of the program, feature short, informal presentations, and offer open time to discuss collaborations with other members. All members of the Basic Sciences Program are invited. Please RSVP by Monday, September 23 to firstname.lastname@example.org.
American Brain Tumor Association
The American Brain Tumor Association is accepting Letters of Intent for the Discovery Grants research program. These awards support high risk/high impact projects that have the potential to change current diagnostic or treatment paradigms for either adult or pediatric brain tumors. Discovery-driven science and proof-of-concept studies are encouraged to apply, particularly those with no or little history of previous funding. Priority will be given to concepts focused on experimental therapeutics and experimental therapeutics with reduced toxicities.
LOI Deadline: October 9
Prostate Cancer Foundation
The Prostate Cancer Foundation is accepting applications for the following opportunities:
- The new 2013 Movember-PCF Challenge Award will support one large-scale research project concerning metastatic prostate cancer over a duration of two years, providing up to a total of $1 million for one team. The award will focus on funding translational and clinical science to advance immunotherapy. Proposals must be from teams of at least three highly experienced investigators capable of providing unique scientific expertise to the solution of a significant problem in prostate cancer research. The team may be assembled from one institution or several institutions from across the globe, and must embed a young investigator as an integral contributor to the team.
Deadline: November 6
- The 2014 Young Investigator Award funds may be used flexibly to advance the career and research efforts of the awardee. Documentation of an equal in-kind level of support will be requested in the form of dedicated space, equipment, institutional overhead, core institutional resources, etc. The documentation required is a letter from the Cancer Center Director or Departmental Chairperson which confirms institutional commitment to the career development of the PCF Young Investigator while under the direct supervision of a Mentor. Mentorship is required for every PCF Young Investigator applicant and grantee.
Deadline: November 13
Robert Wood Johnson Foundation
The Robert Wood Johnson Foundation Health Policy Fellowsprogram provides the nation's most comprehensive fellowship experience at the nexus of health science, policy and politics in Washington, D.C. It is an outstanding opportunity for exceptional midcareer health professionals and behavioral and social scientists with an interest in health and health care policy promoting the health of the nation. Fellows participate in the policy process at the federal level and use that leadership experience to improve health, health care and health policy.
Deadline: November 13
Sidney Kimmel Foundation for Cancer Research
The Sidney Kimmel Foundation for Cancer Research is accepting applications for the following funding opportunities:
- The Kimmel Scholar Award funds accomplished young investigators dedicated to a career in cancer research. Applications are limited to those who achieved the equivalent rank of Assistant Professor on or after July, 2010. However, physicians who have both clinical and research responsibility are eligible if appointed on or after July, 2009. These awards are designed for researchers who do not yet have their own R01 funding.
Deadline: December 4
- The Kimmel Translational Science Award is specifically for physicians engaged in translational science. Eligibility includes those with MD or equivalent degrees, who have achieved the rank of Assistant Professor on or after July, 2009. Candidates must not hold R01 funding for the laboratory component of their cancer research. Applicants must demonstrate a significant personal involvement in the laboratory component of the translational project described. The translational research may involve primarily animal studies but must include reasonable application to subsequent human investigation.
Deadline: December 4